Status:
COMPLETED
SARS-COV-2 Screening in Dialysis Facilities
Lead Sponsor:
Stanford University
Collaborating Sponsors:
National Institute on Minority Health and Health Disparities (NIMHD)
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
End-stage Renal Disease
SARS-CoV-2 Acute Respiratory Disease
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, pati...
Eligibility Criteria
Inclusion
- Facility
- An established US Renal Care in-center hemodialysis facility located in a county with at least two US Renal Care facilities
- Facility governing board (Medical Director, Facility Manager, Social Worker and Charge Nurses) willingness to participate Patient
- Treatment at US Renal Care in-center hemodialysis facility
- Age ≥ 18 years
Exclusion
- Patient
- Unwillingness to share anonymized clinical (electronic health record) or serum samples drawn during routine dialysis care (i.e., without an additional needlestick). If a patient declines offered testing he/she will still be part of the analyses as long as he/she is willing to share clinical data
- Dementia or cognitive impairment, with inability to comprehend 'opting out' of participation
Key Trial Info
Start Date :
February 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2023
Estimated Enrollment :
2389 Patients enrolled
Trial Details
Trial ID
NCT05225298
Start Date
February 6 2023
End Date
October 1 2023
Last Update
October 30 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
US Renal Care
Plano, Texas, United States, 75024